Article Type II NKT Cell Agonist, Sulfatide, Is an Effective Adjuvant for Oral Heat-Killed Cholera Vaccines Aqel Albutti 1,2,† , Stephanie Longet 1,† , Craig P. McEntee 1, Shauna Quinn 1, Alex Liddicoat 1, Cristiana Rîmniceanu 3, Nils Lycke 3, Lydia Lynch 1, Susanna Cardell 3 and Ed C. Lavelle 1,4,* 1 Adjuvant Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, D02 R590 Dublin, Ireland;
[email protected] (A.A.);
[email protected] (S.L.);
[email protected] (C.P.M.);
[email protected] (S.Q.);
[email protected] (A.L.);
[email protected] (L.L.) 2 Department of Medical Biotechnology, College of Applied Medical Sciences, Qassim University, Buraydah 52571, Saudi Arabia 3 Department of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, Box 435, 405 30 Gothenburg, Sweden;
[email protected] (C.R.);
[email protected] (N.L.);
[email protected] (S.C.) 4 Centre for Research on Adaptative Nanostructures and Nanodevices & Advanced Materials Bio-Engineering Research Centre, Trinity College Dublin, D02 PN40 Dublin, Ireland * Correspondence:
[email protected]; Tel.: +353-1-8962488 † These authors contributed equally. Abstract: Oral vaccination has the potential to offer a safer and more efficacious approach for protection against enteric pathogens than injection-based approaches, especially in developing countries. One key advantage is the potential to induce intestinal immune responses in addition to Citation: Albutti, A.; Longet, S.; systemic immunity. In general, antigen delivery via the oral route triggers weak immune responses or McEntee, C.P.; Quinn, S.; Liddicoat, immunological tolerance.